Introduction: Like buprenorphine, methadone is a life-saving medication that can be initiated in the emergency department (ED) to treat patients with an opioid use disorder (OUD). The purpose of this study was to better understand the attitudes of emergency physicians (EP) on offering methadone compared to buprenorphine to patients with OUD in the ED. Methods: We distributed a perception survey to emergency physicians through a national professional network. Results: In this study, the response rate was 18.4% (N = 141), with nearly 70% of the EPs having ordered either buprenorphine or methadone. 75% of EPs strongly or somewhat agreed that buprenorphine was an appropriate treatment for opioid withdrawal and craving, while only 28% agreed that methadone was an appropriate treatment. The perceived barriers to using buprenorphine and methadone in the ED were similar. Conclusion: It is essential to create interventions for EPs to overcome stigma and barriers to methadone initiation in the ED for patients with opioid use disorder. Doing so will offer additional opportunities and pathways for initiation of multiple effective medications for OUD in the ED. Subsequent outpatient treatment linkage may lead to improved treatment retention and decreased morbidity and mortality from ongoing use.
Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.
In response to the rapid escalation in the detection of xylazine in the unregulated drug supply, in April 2023, the White House designated fentanyl contaminated with xylazine an “emerging threat.” The National Institute on Drug Abuse Center for Clinical Trials Network convened a multidisciplinary meeting of stakeholders, federal staff members, researchers, and clinicians caring for patients with fentanyl and xylazine exposures. This convening focused on the most critical areas of concern with the goal of describing current practices and a xylazine-fentanyl research agenda. Discussions focused on the domains of epidemiology and laboratory detection, xylazine withdrawal and overdose, and dermal manifestations. The authors were involved in planning and moderating the program and providing a summary of the proceedings.
1 January 2016 in The Journal of Emergency Medicine
Objectives Trauma exposures and high rates of burnout are widespread among emergency department (ED) clinicians and patients. Trauma-informed care (TIC) education promotes resilience for patients and clinicians. However, there remains a scarcity of data on the impact of TIC on ED clinician outcomes. The objectives of this study were to evaluate post-COVID-19 pandemic professional quality of life among ED clinicians and to test if participation in a TIC education initiative among ED clinicians (1) improves professional quality of life and (2) decreases bias toward patients who misuse opioids. Methods This was a single center, prospective, parallel before-and-after pilot study conducted at a single academic medical center ED. All ED clinicians at our institution participated in a TIC education series and were given the option to participate in the education series in April-May 2023 or be waitlisted to participate in June-July 2023. The validated Professional Quality of Life (ProQOL) scale – V was used to assess compassion satisfaction, burnout, and secondary traumatic stress at baseline (March 2023) and again after the intervention group completed the TIC education (June 2023). The three-month change in the ProQOL subscale scores were compared between the two groups using repeated measures mixed-effects linear regression models. Results Of the 67 included clinicians, 56 selected to receive the TIC education early and 11 subjects selected to be waitlisted. Overall, no clinicians reported a high degree of burnout, secondary traumatic stress, or lack of compassion satisfaction. We did not find a statistically significant difference in the change in scores between the two groups. Conclusions We did not find the TIC education impacted ProQOL scores. This may be due to the low degree of burnout and secondary stress in our cohort.